Patents by Inventor Ester Fernandez-Salas

Ester Fernandez-Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Cancer Using Tachykinin Retargeted Endopepidases
    Publication number: 20110110911
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 16, 2010
    Publication date: May 12, 2011
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • METHODS OF TREATING CANCER USING NEUROTROPHIN RETARGETED ENDOPEPTIDASES
    Publication number: 20110070215
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 16, 2010
    Publication date: March 24, 2011
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • Multivalent Clostridial Toxins
    Publication number: 20110070621
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions may be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 24, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopeptidases
    Publication number: 20110070212
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 16, 2010
    Publication date: March 24, 2011
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • Methods of Treating Cancer Using Galanin Retargeted Endopepidases
    Publication number: 20110070211
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 13, 2010
    Publication date: March 24, 2011
    Inventors: BIRGITTE P.S. JACKY, PATTON E. GARAY, YANIRA MOLINA, DEAN G. STATHAKIS, JOSEPH FRANCIS, KEI ROGER AOKI, ESTER FERNANDEZ-SALAS
  • Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases
    Publication number: 20110070186
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 16, 2010
    Publication date: March 24, 2011
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • Methods of Treating Cancer Using Opioid Retargeted Endopepidases
    Publication number: 20110064713
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 13, 2010
    Publication date: March 17, 2011
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • Activatable clostridial toxins
    Patent number: 7897157
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: March 1, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20110046356
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: February 24, 2011
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translational modifications and Clostridial neurotoxins
    Patent number: 7893202
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translation modification and clostridial neurotoxins
    Patent number: 7888469
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 15, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
    Patent number: 7846722
    Abstract: Clostridial toxin substrates comprising a lanthanide donor complex, an acceptor, and a Clostridial toxin recognition sequence including a cleavage site; methods for determining the activity of a Clostridial toxin from a test sample using such Clostridial toxin substrates; cell compositions comprising such Clostridial toxin substrates and a Clostridial toxin receptor; and methods for determining the activity of a Clostridial toxin from a test sample using such cell compositions.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: December 7, 2010
    Assignee: Allergan, Inc.
    Inventors: Dudley J. Williams, Marcella A. Gilmore, Lance E. Steward, Marc Verhagen, Kei Roger Aoki, Ester Fernandez-Salas
  • CLOSTRIDIAL NEUROTOXIN COMPOSITIONS AND MODIFIED CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100280222
    Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
    Type: Application
    Filed: January 5, 2007
    Publication date: November 4, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd Herrington, Kei Roger Aoki
  • POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273985
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • POST-TRANSLATIONAL MODIFICATION AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273986
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Multivalent clostridial toxins
    Patent number: 7811584
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: October 12, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS
    Publication number: 20100233741
    Abstract: The present specification discloses SNAP-25 immune response inducing compositions, methods of making ?-SNAP-25 antibodies that selectively binds to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond, ?-SNAP-25 antibodies that selectively bind to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond, methods of detecting retargeted endopeptidase activity, and methods of detecting neutralizing ?-re-targeted endopeptidase antibodies.
    Type: Application
    Filed: March 12, 2010
    Publication date: September 16, 2010
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20100233802
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: March 12, 2010
    Publication date: September 16, 2010
    Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Ester Fernandez-Salas
  • Activatable clostridial toxins
    Patent number: 7749514
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: July 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • Cell compositions useful for cell-based FRET assays for clostridial toxins
    Patent number: 7749759
    Abstract: The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: July 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki